The trial achieved each its primary endpoints, with semaglutide 2.four mg demonstrating statistically sizeable and exceptional improvements in liver fibrosis without having worsening of steatohepatitis, and also resolution of steatohepatitis without worsening of liver fibrosis in those with MASH in comparison to placebo.oneThe developmental and hea